COMMUNIQUÉS West-GlobeNewswire

OKYO Pharma Announces Purchase of Shares by Chief Medical Officer
22/07/2026
LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain ( [...]
Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change
22/07/2026
DUBLIN, July 22, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), (the “Company”) today announced that it plans to change the ratio of the American depositary shares (“ADSs”) representing its Class A [...]
Inspire Medical Systems, Inc. Announces Retirement of Casey M. Tansey from its Board of Directors
22/07/2026
MINNEAPOLIS, July 22, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP), a medical technology company focused on innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA [...]
Unnatural Products Appoints Finance Leader Neera Ravindran, M.D., M.B.A., as Chief Financial Officer
22/07/2026
SANTA CRUZ, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Unnatural Products, Inc. (UNP), a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, today announced the appointment [...]
Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases
22/07/2026
RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint. 14 patients with available data from six-month follow-up and biopsy show preliminary 86% (12/14) [...]
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
22/07/2026
BOSTON, July 22, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
Bluesight and Pfizer Partner to Provide Source-Tagged RFID Medications to Hospital Pharmacies
22/07/2026
ALEXANDRIA, Va., July 22, 2026 (GLOBE NEWSWIRE) -- Pfizer’s SmartDose medications arrive pre-tagged and pre-associated for use with KitCheck, reducing manual tagging labor as part of RFID inventory management workflows [...]
BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1
22/07/2026
- PDUFA target action date of May 8, 2027 - If approved, encaleret will be the first and only approved therapy specifically indicated for individuals living with ADH1 , representing a potential blockbuster opportunity [...]
Guidelight Health Opens Eighth Massachusetts Location, Expanding Access to Structured Mental Health Care
22/07/2026
New Andover location and statewide virtual IOP extend timely, evidence-based care across the Commonwealth ANDOVER, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Guidelight Health, a leader in evidence-based mental health [...]
Cannara Announces Normal Course Issuer Bid
22/07/2026
MONTREAL, July 22, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, the “ Company ”, “ us ” or “ we ”) ( TSX: LOVE ) ( OTCQX: LOVFF ) ( FRA: 8CB0 ),a vertically integrated producer of premium-grade cannabis [...]
Lungpacer Announces New Category III CPT® Codes for AeroPace® Diaphragm Neurostimulation Therapy
22/07/2026
New AMA Category III codes, effective July 1, 2026, support the development of future reimbursement pathways for temporary transvenous diaphragm neurostimulation EXTON, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- Lungpacer [...]
Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity
22/07/2026
Virtual Investor "What This Means" segment highlights strategic Whitehawk collaboration, accelerating industry validation of novel ADC payloads, and Akari's differentiated PH1 platform Watch the “What This Means” video [...]
Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy
22/07/2026
First RECIST-confirmed durable Partial Response at current highest dose level #3 (90mCi) with the patient remaining progression free beyond seven months Second patient dosed remains progression free on treatment with [...]
Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call
22/07/2026
BOSTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare [...]
Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026
22/07/2026
BRISBANE, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, [...]
Med X Holdings Announces Official Name Change to Dazed Inc. and New Ticker Symbol "DAZD"
22/07/2026
Welcome to Dazed Inc. Austin, Texas, July 22, 2026 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE Med X Holdings Announces Official Name Change to Dazed Inc. and New Ticker Symbol "DAZD" AUSTIN, Texas – July 21, 2026 – Med X [...]
Oncotelic Announces Peer-Reviewed Publication Validating Deciparticle™ Technology Supporting the Ongoing Clinical Development of Sapu003 (IV everolimus)
22/07/2026
AGOURA HILLS, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Nano today announced the publication of a comprehensive peer-reviewed study in Biomedicines describing the [...]
Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
22/07/2026
WILMETTE, Ill., July 22, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with [...]
Exubrion Therapeutics Promotes Gregory Taglialatela to Chief Commercial Officer
22/07/2026
ATLANTA, July 22, 2026 (GLOBE NEWSWIRE) -- Exubrion Therapeutics ® , the company behind Synovetin OA ® , has promoted Gregory Taglialatela, MBA, to Chief Commercial Officer, effective July 1, 2026. In his new role, [...]

Pages